Day 1 – Wednesday 4th September 2024 - PT (Pacific Time, GMT-08:00)
Day 1 – Wednesday 4th September 2024 - PT (Pacific Time, GMT-08:00)
- Jade Osei-Tutu - Head of RNA Leaders, Senior Conference Director, LSX
- Eugene Yeo - Professor, University Of California San Diego
- Joseph Payne - President & CEO, Arcturus Therapeutics
- From targeting cancer and rare diseases to protein replacement therapies, RNA holds immense promise for tackling numerous healthcare challenges - how does pharma evaluate the potential of the RNA therapeutics landscape?
- What have been the most successful RNA advancements over the last year?
- How does pharma evaluate collaborations with biotech and what technologies are of most interest for a partnership?
- Tamar Grossman - VP, Global Head of RNA & Targeted Therapeutics, Johnson & Johnson
- Jacob Sten Petersen - SVP Nucleic Acid Therapeutics, Novo Nordisk
- Tim Luker - VP Ventures, Eli Lilly & Company
- How do manufacturing assessments differ when considering mass-scale vaccine production versus personalized therapeutics?
- What new RNA production approaches and capacities are required to enable the fulfillment of the potential of mRNA as the core therapeutic and prophylactic platform?
- How is the industry moving to ensure RNA products meet the GMP standards?
- Pad Chivukula - CSO & COO, Arcturus Therapeutics
- Nathaniel Wang - CEO, Replicate Bioscience
- The full potential of these new therapeutics remains in the untapped design space of RNA sequences. Identifying the right format for particular applications, optimizing therapeutic index, on-shelf and in-cell stability, and scaling manufacturing processes are open challenges for the development of successful RNA-based drugs
- Addressing and optimizing for each of these challenges individually will benefit from exploring large areas of RNA design space; addressing all of them requires very large scale, flexible generation of data across multiple RNA formats (mRNA, circRNA, saRNA) and machine learning tools for multiparameter optimization. Using automated, modular workflows and large-scale design and synthesis, we can design, build, and test large RNA libraries to identify and optimize novel elements
- Successful development of RNA therapeutics also requires advances in manufacturing, purification, and delivery methods. Implementation of a proprietary purification workflow of diverse RNA constructs encoding GLuc led to higher purity, prolonged and durable strong expression with reduced dsRNA and cytokine response in cells
- Sarit Schwartz - Business Development, Ginkgo BioWorks
- In this presentation, we will compare two end-to-end oligo-based API synthesis process maps: Codexis’s ECO Synthesis™ manufacturing platform and the current solid-phase phosphoramidite chemistry
- We will present life-cycle analyses of the two manufacturing methods and discuss potential economic benefits and improvements in sustainability metrics of the enzymatic approach
- Matthew Miller - Director, Life Science & RNA Technology, Codexis
Angelman syndrome is a devastating neurogenetic disorder with no effective treatment that is caused by the loss of function of the maternally inherited allele of the ubiquitin protein ligase E3A (UBE3A) gene.The paternal UBE3A allele is imprinted in neurons of the central nervous system by the UBE3A antisense transcript (UBE3A-AS), and reactivating the expression of the paternal UBE3A allele is considered a promising therapeutic option for the treatment of Angelman syndrome.
- Describing the preclinical development of ASOs targeting an evolutionarily conserved region at the start of the human UBE3A-AS transcript.
- Findings show that ASOs targeting this region repress the transcription of UBE3A-AS, reactivating expression of the paternal UBE3A allele in human induced pluripotent stem cell-derived neurons; we further show that human-targeted ASOs administered to the CNS of cynomolgus macaques by lumbar intrathecal injection repress UBE3A-AS and reactivate the expression of the paternal UBE3A allele throughout the CNS, supporting the advancement of this investigational ASO therapy for Angelman syndrome into clinical development
- Scott Dindot - Executive Director of Molecular Genetics, Ultragenyx Pharmaceutical
Showcasing the powerful capabilities of our Sunny Suite platforms = ensuring consistent high-throughput formulation screening through process optimization and pre-clinical scale-up
- Illustrating significant acceleration in LNP formulation screening—performing up to 96 experiments in under 6 hours
- Highlighting the seamless transition to process optimization—adjusting flow rates and ratios—and the effortless scale-up to continuous flow on a single instrument
- Ben Knappett - Market Manager – LNP Solutions, Unchained Labs
- Ionizable lipids are known to present varying degrees of immunotoxicity. Understanding the role of key cellular mediators such as the NLRP3 inflammasome in this context will be key to developing the next generation of safe, well tolerated non-viral delivery systems
- We developed a series of bio-degradable lipids that are rationally engineered to elicit specific immune responses
- Applications of these lipids to create precision mRNA therapeutics and vaccines will be presented
- Syed Reza - Scientific & Sales Consultant, NOF Corporation
- Advancing a lncRNA tailored drug development platform to discover potential therapeutic targets in the dark genome
- Update on early clinical candidate, HTX-001, for treatment of nonobstructive hypertrophic cardiomyopathy
- Samir Ounzain - CEO, HAYA Therapeutics
- Highlighting new prospects of regRNA as an untapped therapeutic target
- Using a programmable next-gen sequencing platform - RAP PlatformTM - to map regRNA and identify ASO drug candidates.
- An update on clinical progression through to dosing studies
- Josh Mandel-Brehm - CEO, Camp4 Therapeutics
Pairing RNA innovation and investment opportunity, like A to U!
New for 2024, The PolymeRAI$E will showcase early-stage innovative RNA biotech companies and their latest scientific advancements. Highlighting new approaches to key industry challenges and exploring technology for new indications. Each company pitch will be evaluated by our Investor Review Panel, formed of senior life science investors and pharma innovation executives.
- Uli Stilz - Head of Bio Innovation Hub, Novo Nordisk Bio Innovation Hub
- Geeta Vemuri - Founder & Managing Partner, Agent Capital
- Hiroki Takai - Director, Investment Group, Global Brain
- Exploring an end-to-end streamlined approach to oligonucleotide drug discovery and development
- Reviewing process development challenges, and looking at simplified customer-based solutions to eliminate regulatory and CMC bottlenecks
- An overview of NCTM’s mRNA production process, from pDNA production to bulk freezing
- A list of QC assays and CQA ranges for the NCTM mRNA platform process
- A summary of the manufacturing-scale, hands-on training course for mRNA production, created in collaboration with industry partner
- Baley Reeves - Director, National Center for Therapeutics Manufacturing
- Leveraging engineered tRNAs to overcome genetic disease
- Using ‘PTCX’ to design tRNAs that recognize and suppress non-sense mutations via insertion of required amino acid
- Insight into new secondary tRNA platform, ‘SWTX’, enabling labelling of disease causing proteins for degradation
- Leslie Williams - CEO, hC Bioscience
- The FORCETM platform harnesses transferrin receptor type 1 biology to deliver therapeutic payloads to muscle and CNS
- FORCETM demonstrates robust efficacy in mouse models of myotonic dystrophy and non-human primates
- DYNE-101 early clinical data show promise for people living with Myotonic Dystrophy Type 1 (DM1)
- Stefan Zanotti - Head of Neuromuscular Research, Dyne Therapeutics
- Utilising ASO drugs to target expanding CAG repeats and reduce pathogenic protein expression associated with multiple polyglutamine diseases, including spinocerebellar ataxia and Huntington’s disease
- Micah Mackinson - CEO, VICO Therapeutics
- Improving delivery and uptake by skeletal and cardiac muscle tissue with the Enhanced Delivery Oligonucleotide (EDO) platform
- Exploring how the EDO platform enhances the uptake, tolerability and activity of oligonucleotide drugs
- Update on clinical trials for Duchenne muscular dystrophy (CONNECT1-EDO51 and CONNECT2-EDO51) and myotonic dystrophy type 1 (FREEDOM1-DM1).
- Jane Larkindale - VP Clinical Science, PepGen
- Investigate the potential of self-amplifying mRNA to create effective immunotherapies for solid tumors
- Evaluate the of safety, tolerability, and efficacy of saRNAs in the clinic
- Karin Jooss - EVP, Head of R&D, Gritstone Bio
The manufacture of high-quality, GMP grade DNA is a major bottleneck in the production of mRNA and viral vectors for use in gene therapy and vaccines.
- Evaluate a scalable, fully enzymatic synthesis process for the production of linear DNA constructs via our Trueprime™ amplification technology
- Compare the synthesis of in vitro transcribed (IVT) mRNA using opDNA™ versus linearised plasmid DNA across a panel of constructs ranging from 1.5kb to 9kb.
- See how the technology can overcome the difficulties associated with complex polyA tails for mRNA constructs, which are inherently difficult to synthesise via bacterial propagation systems
- Amy Walker - VP of Research & Business Development, 4Basebio
- Expanded use of conventional mRNA vaccines has been limited by unacceptable side effects at doses required for protection
- First generation srRNA showed some improvements in bioactivity, but were correspondingly more toxic narrowing their utility
- Here, we show next generation srRNA have major bioactivity improvements clinically, showing capacity to confer protection at very low doses without corresponding increase in toxicity
- Nathaniel Wang - CEO, Replicate Bioscience
- panCAR combines a novel, synthetic, circular coding RNA platform (oRNA) and immunotropic lipid nanoparticles (LNP) to drive CAR expression on surface of multiple immune effector cells after i.v. administration, eliminating the need for external manufacturing.
- LNPs deliver oRNA payloads to immune effector subsets including T cells, NK cells and macrophages in vivo, potentially increasing efficacy and broadening application beyond hematologic malignancies.
- oRNA-enabled panCAR therapies promise a transient, re-dosable and scalable immune cell therapy without requiring immunodepletion
- Robert Mabry - CSO, Orna Therapeutics
- Exploring a tRNA biology platform that utilizes ML and high-throughput automated in vitro assays to design and test tRNA molecules with optimized sequences and chemical modifications
- Developing tRNA therapeutics that identify and correct nonsense mutations (also called premature termination codons) to restore protein production
- Michelle Werner - CEO, Alltrna
- How to engineer vectors for circular-mRNA expression
- Enabling reduced dosing by enhancing payload expression level and potency
- Dual-function gene therapy vectors for a “remove-&-replace” strategy
- Erik Digman Wiklund - CEO, Circio
This workshop will equip RNA developers with the knowledge and strategies to navigate the critical steps in RNA production and delivery processes:
• Scaling IVT mRNA production for clinical applications
• Utilizing novel LNP formulations for efficient mRNA delivery
• Selecting high-quality siRNA for reliable research data
• Implementing robust quality control measures for RNA therapeutics
- Sirat Sikka - Senior Scientist, Applications & Innovation, Thermo Fisher Scientific
- Faster, cleaner, convergent strategy for oligonucleotide assembly
- Fragments are pre-prepared, purified, and stored in a fragment bank
- Fragments are then ligated either biocatalytically or chemically to build up the final oligonucleotide sequence
- Charles Chase - VP, Technical Business Development, Asymchem
- Underlining the influence of endosomal escape on the intracellular activity of oligonucleotide drugs
- Exploring what steps can be taken to overcome endosomal entrapment, and what would this mean for the future of RNA therapeutics
- Steven Dowdy - Professor, University California San Diego
- What new approaches are emerging to address extrahepatic delivery? – moving on from LNPs
- What steps has the industry taken to tackle endosomal escape?
- What analytical challenges need to be considered to overcome delivery boundaries?
- How do delivery limitations influence the target selection process?
- How is the industry moving to develop oligo drug delivery to cancer targets?
- Brad Niles - CEO, Ariz Precision Medicine
- Zdravka Medarova - CTO, TransCode Therapeutics
- Steven Dowdy - Professor, University California San Diego
- Christopher Hart - Co-Founder & CEO, Creyon Bio
- Comprehensive characterization of mRNA therapeutics including detection of dsRNA and off-target cellular changes
- Precision optimization of mRNA therapeutics including codon selection and reduction of miRNA regulation
- Multiomic profiling of siRNA and small molecule targets and direct measurement of off-target binding
- Wayne Doyle - Head of Platform, Eclipse Bioinnovations
- Discussing the opportunities in RNA drug and clinical design
- Optimizing RNA therapeutics through large-scale analysis – what key tools are required?
- What lessons can be learnt from current short and long RNA clinical trials?
- Zelanna Goldberg - CMO, Replicate Bioscience
- Using ImmunoPrism, an ML-based predictive immune modelling platform, to refine predictive biomarkers for immuno-oncology patient response to treatment
- An update on clinical validation studies focussing on HNSCC (Head and Neck Squamous Cell Carcinoma), NSCLC (Non-Small-Cell Lung Cancer), CRC (colorectal cancer) and UCC (urothelial cancer).
- Jarret Glasscock - CEO, Cofactor Genomics
- Advancing a new standardised approach to RNA therapeutic analytics using mass spectrometry
- Driving precise measurement of cellular RNA drug uptake, to improve delivery processes
- Samantha Sarni - Senior Scientist, Regeneron
- Sheng Zhong - Professor, UCSD
Pairing RNA innovation and investment opportunity, like A to U!
New for 2024, The PolymeRAI$E will showcase early-stage innovative RNA biotech companies and their latest scientific advancements. Highlighting new approaches to key industry challenges and exploring technology for new indications. Each company pitch will be evaluated by our Investor Review Panel, formed of senior life science investors and pharma innovation executives.
- Nicholas Mourlas - Head of Johnson & Johnson Innovation, JLABS San Diego, Johnson & Johnson
- Garrett Vygantas - Managing Partner, Riverine Ventures
- Fay Xing - Partner, Panacea Venture
- Leighanne Oh - VP, Ascenta Capital